UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

MIV-711, a highly selective cathepsin K inhibitor, reduces biomarkers of bone resorption and cartilage degradation in healthy subjects

Osteoarthritis and cartilage, 2014-04, Vol.22, p.S197-S197

2014

Volltextzugriff (PDF)

Clinical pharmacokinetics of ranolazine

Clinical pharmacokinetics, 2006-01, Vol.45 (5), p.469-491

JERLING, Markus

2006

Volltextzugriff (PDF)

Insights on Nefecon ® , a Targeted-Release Formulation of Budesonide and Its Selective Immunomodulatory Effects in Patients with IgA Nephropathy

Drug design, development and therapy, 2024-07, Vol.18, p.3415-3428

2024

Volltextzugriff (PDF)

Safety and efficacy of recombinant human platelet derived growth factor (Rhpdgf) in Parkinson's disease

Journal of the neurological sciences, 2013-10, Vol.333, p.e137-e137

2013

Volltextzugriff (PDF)

Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients

The Journal of clinical investigation, 2015-03, Vol.125 (3), p.1339-1346

2015

Volltextzugriff (PDF)

Melflufen - a peptidase-potentiated alkylating agent in clinical trials

Oncotarget, 2017-09, Vol.8 (39), p.66641-66655

2017

Volltextzugriff (PDF)

Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer

Acta oncologica, 2017-01, Vol.56 (3), p.441-447

2017

Volltextzugriff (PDF)

Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine

Clinical pharmacology and therapeutics, 2005-09, Vol.78 (3), p.288-297

2005

Volltextzugriff (PDF)

First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

Investigational new drugs, 2015-12, Vol.33 (6), p.1232-1241

2015

Volltextzugriff (PDF)

A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial

Acta oncologica, 2016, Vol.55 (2), p.140-148

2016

Volltextzugriff (PDF)

Oil‐Fortified Maize Porridge Increases Absorption of Lumefantrine in Children with Uncomplicated Falciparum Malaria

Basic & clinical pharmacology & toxicology, 2017-05, Vol.120 (5), p.457-465

2017

Volltextzugriff (PDF)

Effect of Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ranolazine Sustained-Release Tablets

Journal of clinical pharmacology, 2005-07, Vol.45 (7), p.802-809

2005

Volltextzugriff (PDF)

Effects of intranasal kinetic oscillation stimulation on heart rate variability

Annals of noninvasive electrocardiology, 2018-01, Vol.23 (1), p.n/a

2018

Volltextzugriff (PDF)

Dosing of antidepressants--the unknown art

Journal of clinical psychopharmacology, 1995-12, Vol.15 (6), p.435-439

Jerling, M

1995

Volltextzugriff (PDF)

Intracerebroventricular delivery of vascular endothelial growth factor in patients with amyotrophic lateral sclerosis, a phase I study

Brain communications, 2020-01, Vol.2 (2), p.fcaa160-fcaa160

2020

Volltextzugriff (PDF)

Studies to Investigate the Pharmacokinetic Interactions Between Ranolazine and Ketoconazole, Diltiazem, or Simvastatin During Combined Administration in Healthy Subjects

Journal of clinical pharmacology, 2005-04, Vol.45 (4), p.422-433

2005

Volltextzugriff (PDF)

A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer

Medical oncology (Northwood, London, England), 2015-04, Vol.32 (4), p.129, Article 129

2015

Volltextzugriff (PDF)

Population pharmacokinetics and pharmacodynamics: potential use for gathering dose-concentration-response

European journal of drug metabolism and pharmacokinetics, 1996-04, Vol.21 (2), p.113-121

Jerling, M

1996

Volltextzugriff (PDF)

Comparable Lumefantrine Oral Bioavailability when Co‐administered With Oil‐Fortified Maize Porridge or Milk in Healthy Volunteers

Basic & clinical pharmacology & toxicology, 2013-07, Vol.113 (1), p.66-72

2013

Volltextzugriff (PDF)

Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen

British journal of clinical pharmacology, 2008-04, Vol.65 (4), p.493-501

2008

Volltextzugriff (PDF)

Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6‐an evaluation with the nonparametric maximum likelihood method

British journal of clinical pharmacology, 1994-11, Vol.38 (5), p.453-462

1994

Volltextzugriff (PDF)

Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine : evidence from a therapeutic drug monitoring service

Therapeutic drug monitoring, 1994-08, Vol.16 (4), p.368-374

1994

Volltextzugriff (PDF)

Corrigendum

Basic & clinical pharmacology & toxicology, 2016, Vol.119 (5), p.520

2016

Volltextzugriff (PDF)

Trial to evaluate the management of paroxysmal supraventricular tachycardia during an electrophysiology study with tecadenoson

Circulation (New York, N.Y.), 2005-06, Vol.111 (24), p.3202-3208

2005

Volltextzugriff (PDF)

Comments to "interaction between caffeine and clozapine"

Journal of clinical psychopharmacology, 1995-10, Vol.15 (5), p.376-377

1995

Volltextzugriff (PDF)

1 – 25 von 96

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(93)
Mit Volltextzugriff
(72)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(64)
Life Sciences & Biomedicine
(63)
Science & Technology
(63)
Male
(46)
Female
(41)
Adult
(38)
Middle Aged
(34)
Biological And Medical Sciences
(31)
Medicin Och Hälsovetenskap
(27)
Medical Sciences
(26)
Aged
(21)
Pharmacology & Pharmacy
(21)
Nutrition & Dietetics
(16)
Pharmacology. Drug Treatments
(16)
Diet
(12)
Dose-Response Relationship, Drug
(10)
Adolescent
(9)
Aged, 80 And Over
(9)
Double-Blind Method
(9)
Fundamental And Applied Biological Sciences. Psychology
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

MIV-711, a highly selective cathepsin K inhibitor, reduces biomarkers of bone resorption and cartilage degradation in healthy subjects

Clinical pharmacokinetics of ranolazine

Insights on Nefecon ® , a Targeted-Release Formulation of Budesonide and Its Selective Immunomodulatory Effects in Patients with IgA Nephropathy

Safety and efficacy of recombinant human platelet derived growth factor (Rhpdgf) in Parkinson's disease

Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients

Melflufen - a peptidase-potentiated alkylating agent in clinical trials

Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer

Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine

First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial

Oil‐Fortified Maize Porridge Increases Absorption of Lumefantrine in Children with Uncomplicated Falciparum Malaria

Effect of Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ranolazine Sustained-Release Tablets

Effects of intranasal kinetic oscillation stimulation on heart rate variability

Dosing of antidepressants--the unknown art

Intracerebroventricular delivery of vascular endothelial growth factor in patients with amyotrophic lateral sclerosis, a phase I study

Studies to Investigate the Pharmacokinetic Interactions Between Ranolazine and Ketoconazole, Diltiazem, or Simvastatin During Combined Administration in Healthy Subjects

A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer

Population pharmacokinetics and pharmacodynamics: potential use for gathering dose-concentration-response

Comparable Lumefantrine Oral Bioavailability when Co‐administered With Oil‐Fortified Maize Porridge or Milk in Healthy Volunteers

Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen

Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6‐an evaluation with the nonparametric maximum likelihood method

Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine : evidence from a therapeutic drug monitoring service

Corrigendum

Trial to evaluate the management of paroxysmal supraventricular tachycardia during an electrophysiology study with tecadenoson

Comments to "interaction between caffeine and clozapine"

Suchergebnisse filtern